Group 1 - The core point of the article is that southbound funds have reduced their holdings in Haijia Medical (06078.HK) by 140,200 shares on November 5, 2025, while there have been net increases in holdings on three days over the past five trading days, totaling 2,385,600 shares [1] - Over the last 20 trading days, southbound funds have increased their holdings in Haijia Medical on 14 days, with a total net increase of 7,178,000 shares [1] - As of now, southbound funds hold 203 million shares of Haijia Medical, accounting for 32.76% of the company's total issued ordinary shares [1] Group 2 - On November 5, 2025, the total number of shares held was 203 million, with a decrease of 140,200 shares, reflecting a change of -0.07% [2] - On November 4, 2025, there was an increase of 315,600 shares, representing a change of 0.16% [2] - On November 3, 2025, the increase was 1,771,000 shares, showing a change of 0.88% [2] - Haijia Medical Holdings Limited primarily engages in medical services, focusing on a comprehensive diagnosis and treatment service for tumors, covering multiple stages of cancer diagnosis, treatment, and rehabilitation [2]

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年10月31日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 海吉亞醫療控股有限公司 呈交日期: 2025年11月5日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 (註1) | | 是 | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 06078 | 說明 | 普通股 | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 5,000,000,000 | USD | | 0.00001 | USD | | 50,000 | | 增加 / 減少 (-) | | | | | | | USD | | | | 本月底結存 | | | 5,000,000,000 | USD | | 0.00001 | USD | | 50,000 | 本月底法定 ...

Group 1 - Southbound funds increased their holdings in Hai Ji Ya Medical (06078.HK) by 338,200 shares on October 22, 2025 [1] - Over the past five trading days, there were four days of net increases in holdings, totaling 1,095,800 shares [1] - In the last 20 trading days, there were 15 days of net increases, accumulating to 10,469,800 shares [1] Group 2 - As of now, southbound funds hold 198 million shares of Hai Ji Ya Medical, accounting for 32.04% of the company's issued ordinary shares [1] - The company primarily operates in the medical services sector, focusing on comprehensive cancer diagnosis and treatment services [2] - Hai Ji Ya Medical's hospital business segment provides multidisciplinary medical services, including radiotherapy, chemotherapy, surgery, and targeted therapy [2]

Core Insights - Southbound funds increased their holdings in Hai Ji Ya Medical (06078.HK) by 36,000 shares on October 17, 2025, marking a positive trend in investment interest [1] - Over the past five trading days, there were four days of net increases in holdings, totaling 1,354,400 shares [1] - In the last 20 trading days, there were 15 days of net increases, accumulating to 10,684,200 shares [1] - As of now, southbound funds hold 198 million shares of Hai Ji Ya Medical, representing 31.94% of the company's total issued ordinary shares [1] Trading Data Summary - On October 17, 2025, total shares held were 198 million, with a change of 36,000 shares, reflecting a 0.02% increase [2] - On October 16, 2025, total shares held were 198 million, with a change of 455,800 shares, reflecting a 0.23% increase [2] - On October 15, 2025, total shares held were 197 million, with a change of 2,043,200 shares, reflecting a 1.05% increase [2] - On October 14, 2025, total shares held were 195 million, with a change of 441,800 shares, reflecting a 0.23% increase [2] - On October 13, 2025, total shares held were 195 million, with a change of -1,622,400 shares, reflecting a -0.83% decrease [2] Company Overview - Hai Ji Ya Medical Holdings Limited primarily engages in medical services, focusing on a two-segment operation [2] - The hospital business segment provides comprehensive diagnosis and treatment services for cancer, including multiple disciplines such as radiotherapy, chemotherapy, surgery, and targeted therapy [2] - The company gradually covers all stages of cancer diagnosis, treatment, and rehabilitation [2] - The company mainly operates its business in the domestic market [2]

Core Insights - Southbound funds increased their holdings in Hai Ji Ya Medical (06078.HK) by 2.0432 million shares on October 15, 2025, marking a 1.05% increase in total holdings [1] - Over the past 5 trading days, there were 3 days of net increases, totaling 541,600 shares [1] - In the last 20 trading days, there were 14 days of net increases, amounting to 11.0462 million shares [1] - As of now, southbound funds hold 197 million shares of Hai Ji Ya Medical, representing 31.86% of the company's total issued ordinary shares [1] Company Overview - Hai Ji Ya Medical Holdings Limited primarily engages in medical services, focusing on a comprehensive one-stop diagnosis and treatment service for cancer [2] - The company operates two segments: the hospital business segment, which provides multidisciplinary medical services centered around oncology, including radiotherapy, chemotherapy, surgery, and targeted therapies [2] - The company gradually covers all stages of cancer diagnosis, treatment, and rehabilitation [2] - Hai Ji Ya Medical mainly conducts its business in the domestic market [2]

Core Viewpoint - Hai Jiayi Medical (06078) has issued a profit warning, expecting a revenue decline of approximately 15% to 17% and a net profit decline of about 34% to 39% for the mid-year period [1] Financial Performance - For the first half of 2025, Hai Jiayi Medical reported revenue of 1.99 billion RMB, a year-on-year decrease of 16.47%, and a net profit of 246 million RMB, down 36.18% [3][4] - The company's inpatient services revenue was 1.22 billion RMB (down 18.4% year-on-year) and outpatient services revenue was 722 million RMB (down 11.2% year-on-year) [4] Impact of DRG Payment Reform - The implementation of the DRG (Diagnosis-Related Group) payment reform is a significant factor contributing to the company's financial downturn, shifting the payment model from fee-for-service to bundled payments based on disease types [3][6] - This reform has led to a compression of profit margins for private hospitals, including Hai Jiayi Medical, as it incentivizes cost control rather than revenue maximization [3][6] Market Dynamics - Despite the financial challenges, the demand for hospital services remains stable, with the number of patients treated reaching 2.2 million, unchanged from the previous year [4][6] - The aging population in China, projected to reach over 400 million by 2035, and the expected growth in the oncology market present a favorable long-term outlook for Hai Jiayi Medical [7] Capital Expenditure and Future Strategy - The company has indicated a reduction in capital expenditures, with a current spending of 242 million RMB, down 28.5% year-on-year, and plans to focus on acquisitions rather than building new hospitals in the short term [5][6] - The management believes that the company will eventually see a rebound in revenue and profit as it navigates through the current downturn and capitalizes on new capacity and market concentration [6][7] Stock Performance and Market Sentiment - Hai Jiayi Medical's stock has experienced a significant decline of approximately 87.95% from its peak of 109.43 HKD in 2021 to around 13 HKD, with a static PE ratio dropping to 13.03 times [1][8] - Recent trading activity shows low trading volumes and a bearish sentiment, with the stock price remaining below the average cost, indicating a potential for further downside before any recovery [8][11]

Core Viewpoint - Hai Jiayi Medical (06078) has issued a profit warning, expecting a revenue decline of approximately 15% to 17% and a net profit decline of about 34% to 39% for the mid-year period [1] Financial Performance - For the first half of 2025, Hai Jiayi Medical reported revenue of 1.99 billion RMB, a year-on-year decrease of 16.47%, and a net profit of 246 million RMB, down 36.18% year-on-year [3][4] - The company's inpatient services and outpatient services generated revenues of 1.22 billion RMB (down 18.4% year-on-year) and 722 million RMB (down 11.2% year-on-year) respectively [3][4] DRG Payment Reform Impact - The implementation of the DRG (Diagnosis-Related Group) payment reform is a significant factor contributing to the company's revenue and profit decline, shifting the payment model from fee-for-service to bundled payments based on disease types [3][6] - The reform has led to a compression of profit margins for private hospitals, including Hai Jiayi Medical, as it incentivizes cost control rather than revenue maximization [3][6] Market Dynamics - Despite the revenue and profit declines, the number of patients treated remained stable at 2.2 million, indicating consistent demand for Hai Jiayi's hospital services [4][6] - The aging population in China, projected to reach over 400 million by 2035, and the expected growth in the oncology market present a favorable long-term outlook for Hai Jiayi Medical [7] Capital Expenditure and Future Strategy - The company has indicated a reduction in capital expenditures, with a current spending of 242 million RMB, down 28.5% year-on-year, and plans to focus on acquisitions rather than new hospital constructions in the short term [5][6] - Hai Jiayi Medical is expected to experience a rebound in revenue and profit as it navigates through the capital expenditure peak and benefits from new capacity coming online [6][7] Stock Performance and Market Sentiment - Following the profit warning, the stock price fell significantly, reaching a low of 13.12 HKD, representing an 87.95% decline from its peak of 109.43 HKD in 2021 [1][8] - The stock has shown signs of stabilization, with a recent increase in trading volume and a potential for a turnaround, although market sentiment remains cautious [8][11]

Group 1 - The core point of the article highlights the recent trading activity of southbound funds in Hai Ji Ya Medical, indicating a net increase of 44.18 thousand shares on October 14, 2025, while experiencing a total net reduction of 45.82 thousand shares over the past five trading days [1][2] - Over the last 20 trading days, southbound funds have increased their holdings in Hai Ji Ya Medical for 13 days, resulting in a cumulative net increase of 8.8694 million shares [1][2] - As of now, southbound funds hold a total of 195 million shares of Hai Ji Ya Medical, which accounts for 31.54% of the company's total issued ordinary shares [1][2] Group 2 - Hai Ji Ya Medical Holdings Limited primarily engages in the provision of medical services, focusing on a two-segment operation model [2] - The hospital business segment offers comprehensive diagnosis and treatment services for cancer, including multiple disciplines such as radiotherapy, chemotherapy, surgery, and targeted therapy, covering all stages of cancer diagnosis, treatment, and rehabilitation [2] - The company mainly operates its business in the domestic market [2]

Core Viewpoint - The macro environment and medical insurance payment reform pose challenges to the growth of the comprehensive hospital industry in the short term, as reflected in the company's performance in the first half of 2025. However, the opening of new hospital branches in the second half of 2025 is expected to provide new growth momentum, with revenue growth anticipated to improve compared to the first half of 2025. The company has also shown a commitment to shareholder returns, with consistent stock repurchases and no share reductions by founders since the IPO [1][4]. Financial Performance - In the first half of 2025, the company achieved revenue of 1.99 billion yuan, a year-on-year decrease of 16.47%, and a net profit attributable to shareholders of 247 million yuan, down 35.76%. The earnings per share (EPS) was 0.40 yuan. The board has decided not to recommend any interim dividend for the six months ending June 30, 2025 [1][2]. - The company's gross margin for the first half of 2025 was 26.57%, a decline of 5.19 percentage points year-on-year, primarily due to the increase in fixed costs as a percentage of revenue resulting from the revenue decline [2]. - The core hospital business generated revenue of 1.94 billion yuan, down 15.8% year-on-year, with inpatient revenue at 1.22 billion yuan (down 18.4%) and outpatient revenue at 722 million yuan (down 11.1%) [2][3]. Operational Efficiency - The company reported a significant improvement in operational quality, with net operating cash flow reaching 456 million yuan, a year-on-year increase of 29.9%, and a net cash ratio of 185.4%. Capital expenditures have peaked at 242 million yuan, down 28.5% year-on-year, leading to a substantial increase in free cash flow to 214 million yuan, up 1611.2% [3]. - The company has reduced administrative and non-medical staff by 67 people (5.6% year-on-year) through AI and information technology optimization, indicating a focus on refined management [2][3]. Strategic Development - The company emphasizes the core oncology discipline and is enhancing its technical capabilities to align with DRG/DIP reform requirements. It has signed contracts with nearly 50 commercial insurance companies and is expanding international services for oncology treatment [3][4]. - The company currently operates 16 hospitals, with new projects in Wuxi, Qufu, and Kaiyuan expected to open in 2025, providing a solid foundation for future growth [3][4]. Shareholder Returns - The company has prioritized shareholder returns, with founders and associated parties never reducing their holdings since the IPO and having increased their stakes 22 times. Since September 2024, the company has repurchased and canceled 13.0252 million shares, representing 2.06% of the total shares before cancellation, demonstrating confidence in the company's long-term value [4][5]. Profit Forecast - Due to the performance pressure in the first half of 2025, the company has adjusted its revenue forecasts for 2025-2027, expecting revenues of 3.785 billion yuan, 4.144 billion yuan, and 4.542 billion yuan, with year-on-year growth rates of -14.8%, 9.47%, and 9.6%, respectively. Net profits are projected to be 490 million yuan, 530 million yuan, and 592 million yuan, with year-on-year changes of -18.12%, 8.21%, and 11.60% [5].

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年9月30日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 海吉亞醫療控股有限公司 呈交日期: 2025年10月3日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 (註1) | | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 06078 | 說明 | 普通股 | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 5,000,000,000 | USD | | 0.00001 | USD | | 50,000 | | 增加 / 減少 (-) | | | | | | | USD | | | | 本月底結存 | | | 5,000,000,000 | USD | | 0.00001 | USD | | 50,000 | 本月底法定/ ...